1. BioMarin will host a Q4 2024 earnings call on February 19, 2025. 2. CEO Alexander Hardy will provide business updates and financial results. 3. BioMarin has a strong pipeline with eight commercial therapies. 4. The call will be accessible online and archived for a week.
Earnings calls typically have a temporary impact, depending on results. Past calls have varied in influence on BMRN price.
The earnings call will provide insights into future performance, impacting investor sentiment.
Initial reactions to earnings calls are often short-lived. Long-term trends depend on sustained performance and pipeline developments.
SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 1878833
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1878833
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Marni Kottle
BioMarin Pharmaceutical Inc.
(650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.